Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation?
- PMID: 28493744
- PMCID: PMC5454571
- DOI: 10.1037/pha0000124
Does menthol cigarette use moderate the effect of nicotine metabolism on short-term smoking cessation?
Abstract
The nicotine metabolite ratio (NMR) has been shown to predict response to the transdermal nicotine patch, such that faster nicotine metabolism is associated with a lower abstinence rate. Menthol cigarette use, versus nonmenthol cigarette use, slows nicotine metabolism and therefore may attenuate the effect of NMR on smoking abstinence. In this study, we evaluated whether cigarette type (menthol vs. nonmenthol) modified the association between NMR and short-term abstinence. This was a secondary analysis examining treatment in the first 8 weeks of 21 mg/day nicotine patch therapy in a completed clinical trial (n = 474). Menthol cigarette use was based on self-report. NMR was defined dichotomously (0 = fast, 1 = slow) to distinguish between fast (≥0.47) versus slow NMR. Using logistic regression analysis, we tested whether cigarette type moderated the association between NMR and bioverified 7-day point prevalence abstinence at Week 8. Covariates include nicotine dependence, age, race, and gender. Three hundred two participants reported smoking menthol cigarettes, of which 234 (77%) were classified as slow NMR. Among the 172 nonmenthol smokers, 136 were classified as slow NMR (79%). Contrary to our expectations, the NMR ×Cigarette Type interaction effect on abstinence was not significant (odds ratio [OR] = 0.91, p = .86). Excluding the interaction variable, fast NMR was associated with decreased likelihood of abstinence (OR = 0.55, p = .03), but menthol cigarette use was not (OR = 1.15, p = .56). Further exploration of risk factors among menthol cigarette smokers, especially among racially diverse and light smokers, could clarify the association between menthol cigarette use and poorer smoking outcomes. (PsycINFO Database Record
(c) 2017 APA, all rights reserved).
Conflict of interest statement
Drs. Hitsman and Schnoll receive varenicline and placebo free of charge from Pfizer for use in ongoing National Institutes of Health supported clinical trials. Dr. Hitsman has served on a scientific advisory board for Pfizer. Dr. Schnoll has provided consultation to Pfizer and GlaxoSmithKline. Dr. Tyndale has consulted for Apotex, on unrelated topics. All other authors declare that they have no potential conflicts of interest.
References
-
- Alexander LA, Trinidad DR, Sakuma KL, Pokhrel P, Herzog TA, Clanton MS, … Fagan P. Why We Must Continue to Investigate Menthol’s Role in the African American Smoking Paradox. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2016;18(Suppl 1):S91–101. doi: 10.1093/ntr/ntv209. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
